Omega-3 fatty acids have received increasing interest due to their effects in stabilizing plasmatic membranes and regulating cell signaling. The efficacy of omega-3 fatty acids in psychiatric disorders, in particular mood disorders, has been studied. There have been two trials on eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) in the treatment of borderline personality disorder (BPD). The present 12-week controlled trial aimed to assess the efficacy of the association of EPA and DHA with valproic acid, compared to single valproic acid, in 43 consecutive BPD outpatients. Participants were evaluated at baseline and after 12 weeks with: Clinical Global Impression – Severity (CGI-S), Hamilton Scales for depression and anxiety (HAM-D, HAM-A), Social and Occupational Functioning Assessment Scale (SOFAS), borderline personality disorder severity index (BPDSI), Barratt Impulsiveness Scale – version 11 (BIS-11), Modified Overt Aggression Scale (MOAS), Self-Harm Inventory (SHI) and Dosage Record Treatment Emergent Symptom Scale (DOTES).
American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revised. Washington DC, USA: American Psychiatric Press.
2.
AmmingerGPSchäferMRPapageorgiouK. (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Arch Gen Psychiat67: 146–154.
3.
ArntzAVan den HoornMCornelisJ. (2003) Reliability and validity of the Borderline Personality Disorder Severity Index. J Personal Disord17: 45–59.
4.
AssisiABanziRBuonocoreC. (2006) Fish oil and mental health: The role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders. Int Clin Psychopharmacol21: 319–336.
5.
BarrattES (1965) Factor analysis of some psychometric measures of impulsiveness and anxiety. Psychol Rep16: 547–554.
6.
Buydens-BrancheyLBrancheyM (2008) Long chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers. Psychiatry Res157: 95–104.
7.
Buydens-BrancheyLBrancheyMMcMakinDL. (2003) Polyunsaturated fatty acid status and relapse vulnerability in cocaine addicts. Psychiatry Res120: 29–35.
8.
ChiuCCHuangSYChenCC (2005) Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J Clin Psychiatry66: 1613–1614.
9.
De la PressaOSInnisSM (1999) Docosahexanoic and arachidonic acid prevent a decrease in dopaminergic and serotoninergic neurotrasmitters in frontal cortex caused by a linoleic and alphalinoleic acid deficient diet in formula-fed piglets. J Nutrition129: 2088–2093.
10.
EmsleyRNiehausDJOosthuizenPP. (2008) Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: Results from a randomized, placebo-controlled trial. Psychiat Res161: 284–291.
11.
FirstMBGibbonMSpitzerRL (1997a) Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II). Washington DC: American Psychiatric Press.
12.
FirstMBSpitzerRLGibbonM (1997b) Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). Washington DC: American Psychiatric Press.
13.
FossatiADi CeglieAAcquariniE. (2001) Psychometric properties of an Italian version of the Barratt Impulsiveness Scale-11 (BIS-11) in nonclinical subjects. J Clin Psychol57: 815–828.
14.
FrangouSLewisMMcCroneP (2006) Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: Randomised double-blind placebo-controlled study. Br J Psychiatry188: 46–50.
15.
FrankenburgFRZanariniMC (2002) Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: A double-blind placebo-controlled pilot study. J Clin Psychiatry63: 442–446.
16.
GarlandMRHallahanB (2006) Essential fatty acids and their role in conditions characterised by impulsivity. Int Rev Psychiat18: 99–105.
17.
GarlandMRHallahanBMcNamaraM. (2007) Lipids and essential fatty acids in patients presenting with self-harm. Br J Psychiatry190: 112–117.
18.
GoldmanHHSkodolAELaveTR (1992) Revising Axis V for DSM-IV: A review of measures of social functioning. Am J Psychiatry149: 1148–1156.
19.
GuyW (1976a) Clinical global impression (CGI). In: Early clinical drug evaluation (ECDEU) Assessment Manual for Psychopharmacology. US Department Health, Education, and Welfare publication No. ADM 76–338. Rockville: US National Institute of Mental Health, pp.218–222.
20.
GuyW (1976b) Dosage Record and Treatment Emergent Symptoms scale (DOTES). In: Early clinical drug evaluation (ECDEU) Assessment Manual for Psychopharmacology. US Department Health, Education, and Welfare Publication No. ADM 76-338. Rockville: US National Institute of Mental Health, pp.223–244.
HallahanBHibbelnJRDavisJM. (2007) Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial. Br J Psychiatry190: 118–122.
23.
HamazakiTSawazakiSItomuraM. (1996) The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. J Clin Invest97: 1129–1133.
24.
HamiltonM (1959) The assessment of anxiety states by rating. Br J Med Psychology32: 50–55.
25.
HamiltonM (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry23: 56–62.
26.
HollanderEAllenALopezRP. (2001) A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry62: 199–203.
27.
HollanderESwannACCoccaroEF. (2005) Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry162: 621–624.
28.
HollanderETracyKASwannAC. (2003) Divalproex in the treatment of impulsive aggression: Efficacy in cluster B personality disorders. Neuropsychopharmacol28: 1186–1197.
29.
HorrobinDFGlenAIVaddadiK (1994) The membrane hypothesis of schizophrenia. Schizophr Res13: 195–207.
30.
KaySRWolkenfelfFMurrillLM (1988) Profiles of aggression among psychiatric patients: I. Nature and prevalence. J Nerv Ment Dis176: 539–546.
31.
KeckPEMintzJMcElroySL (2006) Double-blind randomised placebo-controlled trials of ethyl-eicosapentaenoate in the treatment of bipolar depression and rapid-cycling bipolar disorder. Biol Psychiatry60: 1020–1022.
32.
KrawczykKRybakowskiJ (2012) Augmentation of antidepressants with unsaturated fatty acids omega-3 in drug-resistant depression. Psychiatr Pol46: 585–598.
33.
MargariFTMatarazzoRCasacchiaM (2005) Italian validation of MOAS and NOSIE: A useful package for psychiatric assessment and monitoring of aggressive behaviours. Int J Methods Psychiatr Res14: 109–118.
34.
MartinoFMenchettiMPozziE. (2012) Predictors of dropout among personality disorders in a specialist outpatient psychosocial treatment: A preliminary study. Psychiatry Clin Neurosci66: 180–186.
OldhamJM (2005) Guideline Watch: Practice Guideline for The Treatment of Patients with Borderline Personality Disorder. Arlington: American Psychiatric Association.
38.
PattonJHStanfordMSBarrattES (1994) Factor structure of the Barratt Impulsiveness Scale. J Clin Psychol51: 768–774.
39.
RossBMSeguinJSieswerdaLE (2007) Omega-3 fatty acids as treatments for mental illness: Which disorders and which fatty acid?Lipids in Health and Disease6: 21.
40.
SansoneRASansoneLA (2010) Measuring self-harm behavior with the Self-harm Inventory. Psychiatry7: 16–20.
41.
SansoneRAButlerMDakroubH. (2003) Borderline personality symptomatology and employment disability: a survey among outpatients in an internal medicine clinic. Prim Care Companion J Clin Psychiatry8:153–157.
42.
SansoneRAWiedermanMWSansoneLA (1998) The Self-harm Inventory (SHI): Development of a scale for identifying self-destructive behaviors and borderline personality disorder. J Clin Psychol54: 973–983.
43.
SimeonDBakerBChaplinW. (2007) An open-label trial of divalproex extended-release in the treatment of borderline personality disorder. CNS Spectr12: 439–443.
44.
SinnNMilteCHowePR (2010) Oiling the brain: A review of randomized controlled trials of omega-3 fatty acids in psychopathology across the lifespan. Nutrients2: 128–170.
45.
SinnNMilteCMStreetSJ. (2012) Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: A 6-month randomised controlled trial. Br J Nutr107: 1682–1693.
46.
StensbyNE (1969) Nutritional properties of fish-oils. World Rev Nutr Diet11: 46–105.
StollALSeverusWEFreemanMP. (1999) Omega 3 fatty acids in bipolar disorder: A preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry56: 407–412.
49.
ToplissJGClarkAMErnstE (2002) Natural and synthetic substances related to human health. Pure Appl Chem74: 1957–1985.
50.
TownsendMHCambreKMBarbeeJG (2001) Treatment of borderline personality disorder with mood instability with divalproex sodium: Series of 10 cases. J Clin Psychopharmacol21: 249–251.
51.
VirkkunenMEHorrobinDFJenkinsDK. (1987) Plasma phospholipid essential fatty acids and prostaglandins in alcoholic, habitually violent and impulsive offenders. Biol Psychiatry22:1087–1096.
52.
ZanariniMCFrankenburgFR (2003) Omega-3 Fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. Am J Psychiatry160: 167–169.
